457 related articles for article (PubMed ID: 25752908)
21. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis.
Chaudhury P; Hassanain M; Bouganim N; Salman A; Kavan P; Metrakos P
HPB (Oxford); 2010 Feb; 12(1):37-42. PubMed ID: 20495643
[TBL] [Abstract][Full Text] [Related]
22. Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases.
Lubezky N; Winograd E; Papoulas M; Lahat G; Shacham-Shmueli E; Geva R; Nakache R; Klausner J; Ben-Haim M
J Gastrointest Surg; 2013 Mar; 17(3):527-32. PubMed ID: 23299220
[TBL] [Abstract][Full Text] [Related]
23. FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.
Tomasello G; Petrelli F; Ghidini M; Russo A; Passalacqua R; Barni S
JAMA Oncol; 2017 Jul; 3(7):e170278. PubMed ID: 28542671
[TBL] [Abstract][Full Text] [Related]
24. Target hepatic artery regional chemotherapy and bevacizumab perfusion in liver metastatic colorectal cancer after failure of first-line or second-line systemic chemotherapy.
Chen H; Zhang J; Cao G; Liu P; Xu H; Wang X; Zhu X; Gao S; Guo J; Zhu L; Zhang P
Anticancer Drugs; 2016 Feb; 27(2):118-26. PubMed ID: 26566233
[TBL] [Abstract][Full Text] [Related]
25. Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer.
Umehara M; Umehara Y; Takahashi K; Murata A; Nishikawa S; Tokura T; Matsuzaka M; Tanaka R; Morita T
Anticancer Res; 2016 Apr; 36(4):1949-54. PubMed ID: 27069185
[TBL] [Abstract][Full Text] [Related]
26. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
Snoeren N; Voest EE; Bergman AM; Dalesio O; Verheul HM; Tollenaar RA; van der Sijp JR; Schouten SB; Rinkes IH; van Hillegersberg R
BMC Cancer; 2010 Oct; 10():545. PubMed ID: 20937118
[TBL] [Abstract][Full Text] [Related]
27. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
Yoo PS; Lopez-Soler RI; Longo WE; Cha CH
Clin Colorectal Cancer; 2006 Sep; 6(3):202-7. PubMed ID: 17026789
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for
Tang W; Ren L; Liu T; Ye Q; Wei Y; He G; Lin Q; Wang X; Wang M; Liang F; Cui Y; Xu J
J Clin Oncol; 2020 Sep; 38(27):3175-3184. PubMed ID: 32749938
[TBL] [Abstract][Full Text] [Related]
29. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
Bond MJG; Bolhuis K; Loosveld OJL; de Groot JWB; Droogendijk H; Helgason HH; Hendriks MP; Klaase JM; Kazemier G; Liem MSL; Rijken AM; Verhoef C; de Wilt JHW; de Jong KP; Gerhards MF; van Amerongen MJ; Engelbrecht MRW; van Lienden KP; Molenaar IQ; de Valk B; Haberkorn BCM; Kerver ED; Erdkamp F; van Alphen RJ; Mathijssen-van Stein D; Komurcu A; Lopez-Yurda M; Swijnenburg RJ; Punt CJA;
Lancet Oncol; 2023 Jul; 24(7):757-771. PubMed ID: 37329889
[TBL] [Abstract][Full Text] [Related]
30. Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases.
Boilève A; De Cuyper A; Larive A; Mahjoubi L; Najdawi M; Tazdait M; Gelli M; Tselikas L; Smolenschi C; Malka D; Pignon JP; Ducreux M; Boige V
Eur J Cancer; 2020 Oct; 138():89-98. PubMed ID: 32871526
[TBL] [Abstract][Full Text] [Related]
31. OncoSurge: a strategy for long-term survival in metastatic colorectal cancer.
Alberts S; Poston G
Colorectal Dis; 2003 Nov; 5 Suppl 3():20-8. PubMed ID: 23573557
[TBL] [Abstract][Full Text] [Related]
32. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases.
Kishi Y; Zorzi D; Contreras CM; Maru DM; Kopetz S; Ribero D; Motta M; Ravarino N; Risio M; Curley SA; Abdalla EK; Capussotti L; Vauthey JN
Ann Surg Oncol; 2010 Nov; 17(11):2870-6. PubMed ID: 20567921
[TBL] [Abstract][Full Text] [Related]
33. Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection.
Duwe G; Knitter S; Pesthy S; Beierle AS; Bahra M; Schmelzle M; Schmuck RB; Lohneis P; Raschzok N; Öllinger R; Sinn M; Struecker B; Sauer IM; Pratschke J; Andreou A
Eur J Surg Oncol; 2017 Sep; 43(9):1668-1681. PubMed ID: 28599872
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of margin status in liver resections for colorectal metastases after bevacizumab.
Sasaki K; Margonis GA; Andreatos N; Wilson A; Weiss M; Wolfgang C; Sergentanis TN; Polychronidis G; He J; Pawlik TM
Br J Surg; 2017 Jun; 104(7):926-935. PubMed ID: 28266705
[TBL] [Abstract][Full Text] [Related]
35. Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo-adjuvant cytotoxic chemotherapy and bevacizumab.
Eefsen RL; Engelholm L; Willemoe GL; Van den Eynden GG; Laerum OD; Christensen IJ; Rolff HC; Høyer-Hansen G; Osterlind K; Vainer B; Illemann M
Int J Cancer; 2016 Apr; 138(7):1777-84. PubMed ID: 26510166
[TBL] [Abstract][Full Text] [Related]
36. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2014 Sep; 13(3):135-44. PubMed ID: 24768040
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study.
Takatsuki M; Tokunaga S; Uchida S; Sakoda M; Shirabe K; Beppu T; Emi Y; Oki E; Ueno S; Eguchi S; Akagi Y; Ogata Y; Baba H; Natsugoe S; Maehara Y;
Eur J Surg Oncol; 2016 Feb; 42(2):184-9. PubMed ID: 26683263
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysis.
Cui CH; Huang SX; Qi J; Zhu HJ; Huang ZH; Yu JL
Oncotarget; 2015 Dec; 6(41):44005-18. PubMed ID: 26515604
[TBL] [Abstract][Full Text] [Related]
39. Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence.
Mima K; Beppu T; Chikamoto A; Miyamoto Y; Nakagawa S; Kuroki H; Okabe H; Hayashi H; Sakamoto Y; Watanabe M; Kikuchi K; Baba H
Int J Clin Oncol; 2013 Oct; 18(5):847-55. PubMed ID: 22940848
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy Plus Bevacizumab as Neoadjuvant or Conversion Treatment in Patients with Colorectal Liver Metastases.
García-Alfonso P; Cavanagh Podesta M; Muñoz Martín A; Blanco Codeisido M; Calvo A; Peligros I; Corcuera A; Belén Rúperez Blanco A; Custodio-Cabello S; López Trabada D; Martín M; DE Ramón E
Anticancer Res; 2018 May; 38(5):3069-3077. PubMed ID: 29715142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
